PRODUCTION OF
GLYCO-OPTIMIZED PROTEINS

CEVEC’s CAP-Go Technology serves the increasing need for the recombinant production of complexly glycosylated molecules such as coagulation factors and other plasma proteins.

Recombinant proteins expressed on conventional platforms often do not match the glycosylation and pharmacokinetic profiles of their plasma-purified counterparts. CEVEC’s CAP-Go Technology solves this by enabling the high level expression of N- and O-glyco-optimized proteins.

COMPREHENSIVE TOOLBOX OF
CAP®GO CELL LINES

Choose one from our comprehensive panel of CAP-Go cell lines for expressing glycoproteins with:

  • Enhanced sialylation for increased half-life
  • Reduced antennary fucosylation
  • High degree of galactosylation of N-glycans
  • High or low N-glycan antennarity as required
  • Homogenous tailored O-glycosylation patterns
  • Human plasma identical glycans
  • Proper folding and secretion

HUMAN CELLS FOR
HUMAN GLYCOSYLATION PATTERN

  • Authentic human glycosylation for complex proteins
  • No immunogenic non-human carbohydrate residues
  • High specific activity

HIGH PRODUCT TITERS

  • Up to 10 times higher titer than conventional cell lines
  • Minimal product aggregation
  • Cost effective large scale production

REDUCED PRODUCTION COST

  • Consistent protein quality resulting in reduced downstream costs
  • Minimal batch-to-batch variations
  • Homogenous glycosylation patterns

CONTRACT MANUFACTURING
OF GLYCO-OPTIMIZED PROTEINS

We provide full CMC Support up to Phase II Clinical Materials and Licenses to the CAP-Go Technology for your pharmaceutical product.

  • Cell line development using the appropriate CAP-Go line
  • Process development
  • cGMP cell banking
  • Bulk protein production
  • Fill and finish

CAP®GO EXAMPLES

  • Plasma Proteins
  • Cytokines
  • Ion Channels
  • Virus Envelope Proteins
  • High Molecular Mass Multimer Proteins
  • Antibodies